John A Hamilton Selected Research

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)

1/2022	Type I interferon antagonism of the JMJD3-IRF4 pathway modulates macrophage activation and polarization.
1/2022	The role of interleukin (IL)-23 in regulating pain in arthritis.
1/2021	Targeting GM-CSF in inflammatory and autoimmune disorders.
11/2020	Granulocyte-Macrophage Colony Stimulating Factor As an Indirect Mediator of Nociceptor Activation and Pain.
1/2020	GM-CSF in inflammation.
1/2020	Inhibition of purinergic P2X receptor 7 (P2X7R) decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) expression in U251 glioblastoma cells.
1/2020	CCL17 in Inflammation and Pain.
1/2020	GM-CSF: A Promising Target in Inflammation and Autoimmunity.
1/2020	IL-23 in arthritic and inflammatory pain development in mice.
1/2020	GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John A Hamilton Research Topics

Disease

35	Inflammation (Inflammations) 01/2022 - 08/2002
19	Arthritis (Polyarthritis) 01/2022 - 08/2002
18	Pain (Aches) 01/2022 - 11/2009
16	Rheumatoid Arthritis 01/2020 - 03/2002
8	Peritonitis 01/2019 - 11/2003
7	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 08/2002
7	Neoplasms (Cancer) 01/2020 - 06/2009
6	Pneumonia (Pneumonitis) 01/2020 - 04/2004
6	Infections 01/2018 - 04/2004
4	Disease Progression 01/2016 - 08/2002
3	Necrosis 01/2020 - 08/2002
3	Neoplasm Metastasis (Metastasis) 01/2018 - 08/2014
3	Chronic Obstructive Pulmonary Disease (COPD) 09/2014 - 11/2002
3	Experimental Arthritis 08/2011 - 03/2002
2	Osteoarthritis 01/2018 - 09/2012
2	Neutropenia 01/2018 - 01/2018
2	Breast Neoplasms (Breast Cancer) 01/2018 - 08/2014
2	Periodontitis 09/2015 - 06/2015
2	Wounds and Injuries (Trauma) 05/2014 - 01/2010
2	Stroke (Strokes) 04/2014 - 12/2013
2	Substance-Related Disorders (Drug Abuse) 04/2012 - 07/2006
2	Hypoxia (Hypoxemia) 01/2012 - 06/2009
1	Psoriatic Arthritis 01/2022
1	Chronic Pain 11/2020
1	Immune System Diseases (Immune Disorders) 01/2020
1	COVID-19 01/2020
1	Glioblastoma (Glioblastoma Multiforme) 01/2020
1	Febrile Neutropenia 01/2018
1	Osteophyte 01/2018
1	Chronic Periodontitis 01/2017
1	Alveolar Bone Loss 09/2015

Drug/Important Bio-Agent (IBA)

38	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2022 - 08/2002
21	CytokinesIBA 01/2022 - 08/2002
10	Macrophage Colony-Stimulating FactorIBA 10/2018 - 06/2002
6	Monoclonal AntibodiesIBA 01/2022 - 08/2011
6	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2018 - 08/2014
6	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 06/2015 - 03/2002
5	ZymosanIBA 01/2020 - 01/2017
5	methylated bovine serum albumin (MBSA)IBA 01/2020 - 11/2003
5	Fibrinolysin FDA Link 06/2015 - 09/2002
5	Plasminogen Activators (Plasminogen Activator)IBA 06/2015 - 03/2002
4	AntigensIBA 12/2016 - 01/2010
4	LipopolysaccharidesIBA 01/2011 - 11/2002
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2004 - 08/2002
3	LigandsIBA 01/2020 - 12/2009
3	CollagenIBA 04/2016 - 01/2011
3	Antigen-Antibody Complex (Immune Complex)IBA 01/2016 - 01/2010
3	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2016 - 05/2003
3	Tissue Plasminogen Activator (Alteplase)FDA Link 11/2012 - 03/2002
2	Interleukin-17 (Interleukin 17)IBA 01/2022 - 01/2020
2	Interleukin-23 (Interleukin 23)IBA 01/2022 - 01/2020
2	Nerve Growth Factor (NGF)IBA 11/2020 - 01/2020
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2020 - 02/2013
2	Indomethacin (Indometacin)FDA LinkGeneric 01/2020 - 02/2013
2	Tumor Necrosis Factor InhibitorsIBA 01/2019 - 02/2018
2	Interleukin-1 (Interleukin 1)IBA 01/2019 - 08/2002
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2018 - 01/2017
2	Collagenases (Collagenase)FDA Link 01/2018 - 09/2012
2	Granulocyte Colony-Stimulating Factor Receptors (G-CSF Receptor)IBA 01/2017 - 08/2014
2	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 12/2016 - 07/2008
2	Interleukin-6 (Interleukin 6)IBA 12/2016 - 03/2008
2	AutoantibodiesIBA 01/2016 - 05/2013
2	ChemokinesIBA 01/2016 - 01/2016
2	Neutralizing AntibodiesIBA 08/2014 - 04/2004
2	Rosiglitazone (Avandia)FDA Link 04/2014 - 12/2013
2	Matrix Metalloproteinases (MMPs)IBA 09/2012 - 04/2004
2	Macrophage Colony-Stimulating Factor Receptor (Receptor, Macrophage Colony Stimulating Factor)IBA 04/2012 - 01/2012
2	Proteins (Proteins, Gene)FDA Link 02/2011 - 01/2005
2	FibrinIBA 04/2006 - 03/2002
2	EndotoxinsIBA 04/2004 - 05/2003
1	Interleukin-23 Subunit p19IBA 01/2022
1	InterleukinsIBA 01/2022
1	guselkumabIBA 01/2022
1	Biological ProductsIBA 01/2021
1	Conditioned Culture MediaIBA 11/2020
1	Substance PIBA 01/2020
1	AZ10606120IBA 01/2020
1	EicosanoidsIBA 01/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020
1	GlucocorticoidsIBA 01/2019
1	Methotrexate (Mexate)FDA LinkGeneric 01/2019
1	mavrilimumabIBA 02/2018
1	Biomarkers (Surrogate Marker)IBA 02/2018
1	CCR4 ReceptorsIBA 01/2018
1	Cell Surface ReceptorsIBA 01/2017
1	InflammasomesIBA 01/2017
1	Interleukin-3 (Interleukin 3)IBA 12/2016
1	IntegrinsIBA 01/2016
1	AutoantigensIBA 01/2016
1	Fc Receptors (Fc Receptor)IBA 01/2016
1	Complement System Proteins (Complement)IBA 01/2016
1	PlasminogenIBA 06/2015
1	Extracellular Matrix ProteinsIBA 04/2015
1	Nicotinic AgonistsIBA 03/2015
1	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 03/2015
1	Muscarinic AgonistsIBA 03/2015

Therapy/Procedure

10	Therapeutics 01/2020 - 04/2007
2	Drug Therapy (Chemotherapy) 01/2018 - 01/2018
1	Investigational Therapies (Experimental Therapy) 02/2018
1	Drug Tapering 01/2018